Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Influenza
Interventions: DAS181, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 54
States / cities: Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more

Conditions: Parkinson's Disease
Interventions: CVT-301, LIP, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 11
States / cities: Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more

Conditions: Asthma
Interventions: Fluticasone propionate 100mcg, Placebo, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 31 more

Conditions: Asthma
Interventions: Fp/ABS, FP, ABS, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 12 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 91
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more

Conditions: Allergic Bronchopulmonary Aspergillosis
Interventions: PUR1900, Placebo; Combination Product
Lead sponsor: Pulmatrix Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more

Conditions: Asthma, Dental Caries
Interventions: Chinese Licorice Root; Dietary Supplement
Lead sponsor: University of Nebraska; Other
Eligibility: 4 Years to 16 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Lakewood, California + 46 more

Conditions: Asthma
Interventions: tiotropium 5mcg/day, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more

Conditions: Tobacco Abuse Smoke
Interventions: Fluticasone, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol (BI1744), placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 21
States / cities: Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more

Conditions: COPD Exacerbation
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Tarzana, California • Torrance, California + 4 more

Conditions: Asthma
Interventions: Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF; Drug
Lead sponsor: Novartis; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 53
States / cities: Anaheim, California • Escondido, California • Riverside, California + 45 more

Conditions: Chronic Obstructive Pulmonary Disease, Sleep Disorders
Interventions: salmeterol-fluticasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: beclomethasone dipropionate (QVAR); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 31
States / cities: Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 27 more

Conditions: Cystic Fibrosis
Interventions: tiotropium Respimat® inhaler, Placebo Respimat® inhaler; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 15
States / cities: Tuscon, Arizona • San Diego, California • Jacksonville, Florida + 10 more

Conditions: Asthma
Interventions: Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 12 Years and older
Enrollment: 1,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 100
States / cities: Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more

Conditions: COPD
Interventions: GFF MDI (PT003), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 44
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more

Conditions: Asthma
Interventions: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler, Placebo via DISKUS / ACCUHALER; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more

Conditions: Asthma
Interventions: fluticasone propionate, fluticasone propionate/salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Huntington Beach, California • Long Beach, California • Riverside, California + 16 more

Search by objective public record fields.

Influenza Antiviral DAS-181-F04 in Healthy Adults

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers

12 / 48 Week Pivotal PFT vs PBO in COPD I

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids

Tiotropium Bromide in Cystic Fibrosis

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma